SCHEMBL2835178

SCHEMBL2835178

Cc1ccccc1OC(=O)c1cccc(F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.60
ALDH1A1 P00352 3/20 0.60
ESR1 P03372 2/20 0.54
ESR2 Q92731 2/20 0.54
PKM P14618 2/20 0.49
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
MEN1 O00255 3/20 0.48
LMNA P02545 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 1/20 0.48
TSHR P16473 1/20 0.48
SLC2A1 P11166 1/20 0.48
SLC2A4 P14672 1/20 0.48
MAPT P10636 3/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
POLB P06746 2/20 0.47
THRB P10828 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2829946 0.89 KMT2A (0.63) KMT2AALDH1A1ESR1ESR2PKM
SCHEMBL2829948 0.85 KMT2A (0.69) KMT2AALDH1A1ESR1ESR2CES2
SCHEMBL2838742 0.84 SLC2A1 (0.57) KMT2AALDH1A1ESR1ESR2PKM
SCHEMBL15851050 0.84 KMT2A (0.64) KMT2AALDH1A1ESR1ESR2MEN1
SCHEMBL2831997 0.83 KMT2A (0.54) KMT2AESR1ESR2PKMMEN1
SCHEMBL10921648 0.83 SLC2A1 (0.60) KMT2AESR1ESR2MEN1RAB9A
SCHEMBL1284160 0.81 KMT2A (0.63) KMT2AESR1ESR2MEN1LMNA
SCHEMBL14055345 0.81 KMT2A (0.59) KMT2AALDH1A1ESR1ESR2PKM
SCHEMBL14206780 0.80 ESR1 (0.60) KMT2AESR1ESR2CES2CES1
SCHEMBL28678134 0.79 POLB (0.57) KMT2AESR1ESR2MEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263268-B2 Ester compound, and non-aqueous electrolyte solution and lithium secondary battery each using the ester compound UBE INDUSTRIES, LTD. (JP) 2012-09-11 US disclosed
EP-2108640-B1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES (JP) 2012-07-25 EP disclosed
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND UBE INDUSTRIES, LTD. (JP) 2010-05-13 US disclosed
EP-2108640-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND Ube Industries, Ltd. (JP) 2009-10-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100119955-A1 ESTER COMPOUND, AND NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY EACH USING THE ESTER COMPOUND CEL, LAGE3, PEF1 KMT2A 1023/4885ALDH1A1 2511/4885ESR1 119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.